WEIGUANG BIOLOGICAL(SZ:002880) Xin Lang Zheng Quan·2025-10-30 12:07Core Viewpoint - Weigao Bio is a significant player in the domestic blood products sector, focusing on the production and research of blood products, with a strong technical barrier and a diverse product line [1] Group 1: Business Performance - In Q3 2025, Weigao Bio reported revenue of 791 million, ranking 5th in the industry, with the top competitor, Shanghai Raas, generating 6.091 billion [2] - The company's net profit for the same period was 158 million, also ranking 5th, while the industry leader reported a net profit of 1.47 billion [2] Group 2: Financial Ratios - As of Q3 2025, Weigao Bio's debt-to-asset ratio was 30.56%, higher than the industry average of 28.01% [3] - The gross profit margin for Q3 2025 was 42.47%, which is below the industry average of 44.76% [3] Group 3: Executive Compensation - The chairman, Zhang Zhan, received a salary of 1.2442 million in 2024, an increase of 21,600 from 2023 [4] - The general manager, Guo Caiping, also received a salary of 1.2442 million in 2024, up by 33,800 from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.70% to 12,500, while the average number of shares held per shareholder increased by 0.70% to 18,100 [5] - Hong Kong Central Clearing Limited became a new major shareholder, holding 679,400 shares [5] Group 5: Future Outlook - Huazheng Securities predicts that Weigao Bio will achieve revenue and profit growth in 2024, with a notable increase in non-recurring net profit [5] - The company is expected to see revenue of 1.347 billion, 1.497 billion, and 1.653 billion from 2025 to 2027, with net profits of 299 million, 345 million, and 396 million respectively [5] - Zhongyou Securities anticipates steady growth in 2024, with a recovery in blood product business expected [6]